pharma · Osteoarthritis · Pain
Mundipharma
Mundipharma Pty Limited
Mundipharma Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Osteoarthritis, Pain, Chronic pulmonary aspergillosis (CPA). NovaPharmaNews links 4 clinical program(s), 3 dru
Sydney, AU HQ
1952 Founded
2,082 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, AU
- Founded
- 1952
- Employees
- 2,082
- Programs
- 4
- Drugs
- 23
- Patents
- 0
REZZAYO 200 mg powder for concentrate for solution for infusion
Phase 2 · small molecule · Chronic pulmonary aspergillosis (CPA)
REZZAYO 200 mg powder for concentrate for solution for infusion for Chronic pulmonary aspergillosis (CPA) is a Phase 2 program (small_molecule) at Mundipharma Pty Limited with 1 ClinicalTrials.gov record(s).
Internal code MR907-2502
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mundipharma Pty Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Chronic pulmonary aspergillosis (CPA)
- Status
- active
- Trials
- 1